Ex-Fisker Workers Accuse EV Startup Of Launching Products With No Repair Plan As ‘They Truly Thought They Built The Perfect Car:’ Report
The company instead relied on sourcing components from disassembled cars, they claimed.
Gear Shift In Japan: Toyota & Other Auto Giants Reportedly Under Inspection Over Certification Scandal
Japan's transport ministry inspected Toyota Motor Corporation's headquarters and found irregularities, leading to broader repercussions in the industry.
Microsoft Faces Privacy Wrath Over Education Suite: Report
Microsoft reportedly faces scrutiny over privacy concerns in its online education software. NOYB alleges violations of EU regulations, prompting an investigation by the Austrian Data Protection Authority.
‘So Much Is Wrong:’ Short-Seller Andrew Left Says ‘Roaring Kitty’ Trying To Take Advantage Of Retail Traders After Revealing Huge GameStop Position
"He puts this monster position, no thesis...short-term options. I personally do not believe this is his own personal money."
Microsoft, Google Announce Hundreds Of Job Cuts In Tech Departments Despite Robust Financials
Satya Nadella-led Microsoft and Sundar Pichai's Alphabet have announced significant layoffs, impacting hundreds of employees across various departments, despite strong financial performances in the first quarter of 2024.
Xi Jinping’s China Wants To ‘Delete’ America After Nvidia, Others Forced To Curb High-End Chip Exports To Beijing, But Are Biden Administration’s Policies Waking Up A ‘Sleeping Lion’
China's Semiconductor Manufacturing International Corp. (SMIC) is ramping up chip production using domestic tools at its new Jingcheng facility, aiming to counteract U.S. export restrictions and reduce reliance on American technology.
Morgan Stanley’s E*Trade Mulls Roaring Kitty Ban Over Alleged Stock Manipulation: Report
Morgan Stanley may ban Keith Gill from E*Trade due to concerns of manipulating meme stock prices through social media. Gill's actions have led to increased volatility and sparked debates within the firm.
GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with potential milestones and royalties up to $577 million.
Alibaba’s 618 Shopping Festival Boosts Sales with Big Brands Like Apple, Xiaomi Leading the Way
Alibaba's 618 shopping festival saw strong momentum with over 185 brands achieving high sales and support for their goal of double-digit revenue growth.